The generic brand name for Nurtec ODT is rimegepant [1].
How does rimegepant work?
Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist [1]. It works by blocking the activity of CGRP, a molecule involved in migraine pain [2].
When might rimegepant become available as a generic?
The U.S. Food and Drug Administration (FDA) approved rimegepant (brand name Nurtec ODT) in December 2019 for the acute treatment of migraine with or without aura in adults [1]. The drug's patents are expected to expire in the coming years, potentially leading to generic availability. Information regarding specific patent expiry dates can be found on DrugPatentWatch.com [3].
What are the other uses for Nurtec ODT (rimegepant)?
In addition to the acute treatment of migraine, rimegepant is also approved for the preventive treatment of episodic migraine in adults [1].
How does Nurtec ODT compare to other migraine treatments?
Nurtec ODT is a CGRP antagonist, a class of drugs that differs from older migraine treatments like triptans, which target serotonin receptors [2]. Rimegepant offers a different mechanism of action and can be used for both acute treatment and prevention of migraines [1].
What are the potential risks or side effects of rimegepant?
Common side effects of rimegepant can include nausea and upper abdominal pain [1]. Patients should discuss any potential risks with their healthcare provider.